Balloon pulmonary angioplasty in chronic pulmonary thromboembolic pulmonary hypertension
Journal
Acta Cardiologica Sinica
Journal Volume
35
Journal Issue
2
Pages
183–187
Date Issued
2019-03-01
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare disease, caused by obstruction and incomplete resolution of thrombus and further remodeling of the pulmonary artery. The treatment of CTEPH depends on the location of the obstruction and its surgical accessibility.1 In operable CTEPH, pulmonary endarterectomy (PEA) remains the treatment of choice.1 In the authors’ experience, PEA may be conducted safely with a relatively low risk, and patients who undergo successful PEA have a significant improvement in their clinical status and hemodynamic data.2 However, in patients with inoperable CTEPH, lifelong anticoagulant use is recommended, as well as riociguat. In addition, balloon pulmonary angioplasty (BPA) is emerging as a promising alternative treatment option, with hemodynamic and functional improvement and acceptable complication rates.1 The present study reports the first case of inoperable CTEPH receiving BPA treatment in Taiwan.
SDGs
Type
journal article